Suriyanarayanan S1,2, Othman A3, Dräger B4, Schirmacher A4, Young P4, Mulahasanovic L5, Hörtnagel K5, Biskup S5, von Eckardstein A3,6, Hornemann T3,6, Lone MA3.
- Institute for Clinical Chemistry, University Hospital Zurich, University of Zurich, Wagistrasse 14 Schlieren, 8952, Zurich, Switzerland. Saranya.Suriyanarayanan@usz.ch.
- Competence Center for Personalized Medicine (CC-PM), Zurich, Switzerland. Saranya.Suriyanarayanan@usz.ch.
- Institute for Clinical Chemistry, University Hospital Zurich, University of Zurich, Wagistrasse 14 Schlieren, 8952, Zurich, Switzerland.
- Department of Sleep Medicine and Neuromuscular Disorders, University Hospital of Muenster, Muenster, Germany.
- CeGaT GmbH and Praxis für Humangenetik Tübingen, Tübingen, Germany.
- Competence Center for Personalized Medicine (CC-PM), Zurich, Switzerland.
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is a rare, autosomal dominantly inherited, slowly progressive and length-dependent axonal peripheral neuropathy. HSAN1 is associated with several mutations in serine-palmitoyltransferase (SPT), the first enzyme in the de novo sphingolipid biosynthetic pathway. HSAN1 mutations alter the substrate specificity of SPT, which leads to the formation of 1-deoxysphingolipids, an atypical and neurotoxic subclass of sphingolipids. This study describes the clinical and neurophysiological phenotype of a German family with a novel SPTCL2 mutation (c.529A > G; N177D) associated with HSAN1 and the biochemical characterization of this mutation.) The mutaion was identified in five family members that segregated with the diesease. Patients were characterized genetically and clinically for neurophysiological function. Their plasma sphingolipid profiles were analyzed by LC-MS. The biochemical properties of the mutation were characterized in a cell-based activity assay. Affected family members showed elevated 1-deoxysphingolipid plasma levels. HEK293 cells expressing the N177D SPTLC2 mutant showed increased de novo 1-deoxysphingolipid formation, but also displayed elevated canonical SPT activity and increased C20 sphingoid base production. This study identifies the SPTLC2 N177D variant as a novel disease-causing mutation with increased 1-deoxySL formation and its association with a typical HSAN1 phenotype.
1-deoxysphingolipids; HSAN1; Mass spectrometry; Neuropathy; Serine-palmitoyltransferase